Adagene Inc (ADAG)

[StockLogistics]

“Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies”

“Another exciting and surprising aspect of these interim findings is that we see early signals of efficacy in certain ‘cold’ tumors with SAFEbody ADG126, which further builds on prior clinical evidence with its parental antibody ADG116, targeting a unique epitope of CTLA-4 to enable not only a safer but potentially better therapy than the options we have available today.”

““Following these monotherapy dose escalation results, we look forward to releasing further data in coming months to confirm if the strong safety profile of ADG126 is preserved in combination with anti-PD-1 therapy, consistent with our preclinical observations,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.”

6-K 05/26/2022

https://www.otcmarkets.com/filing/html?id=15852709&guid=pD9-kWAqNv9JqBh